ConductScience.org, home

Paper39682109

The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies.

Yacoub I and 7 others. Cancers (Basel), 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies. Papers, record 39682109. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39682109

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.0, provisional
iCite
Revised in PubMed
2025-01-31
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yacoub IIrini
2Rayn KKareem
3Choi JIJ Isabelle
4Bakst RRichard
5Chhabra AArpit
6Qian JYJoshua Yhttps://orcid.org/0000-0002-3094-9052
7Johnstone PPeterhttps://orcid.org/0000-0003-4221-9388
8Simone CB 2ndCharles Bhttps://orcid.org/0000-0002-0867-3694

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed

Source NIH RePORTER

Download CSV of grants

References127

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127245173Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.J Natl Cancer Inst2016https://conductscience.org/library/papers/27245173PubMed
227717298Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.N Engl J Med2016https://conductscience.org/library/papers/27717298PubMed
329573941Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol2018https://conductscience.org/library/papers/29573941PubMed
430422243Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.JAMA Oncol2019https://conductscience.org/library/papers/30422243PubMed
511240248Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis.Int J Radiat Oncol Biol Phys2001https://conductscience.org/library/papers/11240248PubMed
632613057Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series.JAAD Case Rep2020https://conductscience.org/library/papers/32613057PubMed
725993155Achievements and challenges of molecular targeted therapy in melanoma.Am Soc Clin Oncol Educ Book2015https://conductscience.org/library/papers/25993155PubMed
832087988Completion lymph node dissection for merkel cell carcinoma.Am J Surg2020https://conductscience.org/library/papers/32087988PubMed
926206146
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
Lancet Oncol2015https://conductscience.org/library/papers/26206146PubMed
1031166680Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.N Engl J Med2019https://conductscience.org/library/papers/31166680PubMed
1114576661Epidemiology of primary Merkel cell carcinoma in the United States.J Am Acad Dermatol2003https://conductscience.org/library/papers/14576661PubMed
129307187The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma.Cancer1997https://conductscience.org/library/papers/9307187PubMed
1335661157Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.Nat Med2022https://conductscience.org/library/papers/35661157PubMed
1434015514Survival Benefit of Guideline-Concordant Postoperative Radiation for Local Merkel Cell Carcinoma.J Surg Res2021https://conductscience.org/library/papers/34015514PubMed
154038911Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin.Cancer1985https://conductscience.org/library/papers/4038911PubMed
1620525992Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010https://conductscience.org/library/papers/20525992PubMed
1710935303Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature.Ear Nose Throat J2000https://conductscience.org/library/papers/10935303PubMed
1811713722Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage.Am J Otolaryngol2001https://conductscience.org/library/papers/11713722PubMed
1923200197Prognostic factors in Merkel cell carcinoma: analysis of 240 cases.J Am Acad Dermatol2013https://conductscience.org/library/papers/23200197PubMed
2025795410Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol2015https://conductscience.org/library/papers/25795410PubMed

See all 127 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
41010750Radiotherapeutic Modalities and Advancements in the Treatment of Cutaneous Malignancies.J Clin Med2025https://conductscience.org/library/papers/41010750PubMed
40333816C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma.PLoS One2025https://conductscience.org/library/papers/40333816PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39682109

GET https://conductscience.org/api/papers/v1/39682109/references?page=2